Evaluation of bioequivalence of two formulations containing 100 milligrams of aceclofenac

Drug Development and Industrial Pharmacy

Volumn 32, Issue 10, 2006, Pages 1219-1225

  Gowda, K V ^a   Rajan, D S ^a   Mandal, U ^a   Selvan, P S ^a   Solomon, W D Sam ^a   Bose, A ^a   Sarkar, A K ^a   Pal, T K ^a   Chattaraj, T K ^b  

^a JADAVPUR UNIVERSITY   (India)

^b NRS MEDICAL COLLEGE   (India)

Author keywords

Aceclofenac; Bioequivalence; HPLC; Pharmacokinetics

Indexed keywords

ACECLOFENAC; HIFENAC;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; ULTRAVIOLET SPECTROSCOPY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DICLOFENAC; DRUG EVALUATION; DRUGS, GENERIC; HUMANS; INDIA; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY;

EID: 33750877638     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040600608805     Document Type: Article

References (18)

1. Bort, R., Ponsoda, X., Carrasco, E., Gomez-Lechon, M. J., & Castell, J. V. (1996). Metabolism of aceclofenac in humans. Drug Metab. Dispos., 24, 834-841.
2. Brogden, R. N., & Wiseman L. R. (1996). Aceclofenac: a review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Drugs, 52, 113-124.
3. Committee for Proprietary Medicinal Products (CPMP). (1991). Note for Guidance: Investigation of Bioavailability and Bioequivalence. London: Working Party on the Efficacy of the Medicinal Products.
4. El Kousy, N. M. (1999). Spectrophotometric and spectrofluorimetric determination of etodolac and aceclofenac. J. Pharm. Biomed. Anal., 20, 185-194.
5. Farolfi, M., Power, J. D., & Rescigno, A. (1999). On the determination of bioequivalence. Pharmacol. Res., 39, 1-4.
6. Hanses, A., Saphn-Langguth, H., & Mutschler, E. (1995). A new rapid and sensitive high performance liquid chromatographic assay for diclofenac in human plasma. Archiv der Pharmazie, 328, 257-260.
7. Hasan, N. Y., Abdel-Elkawy, M., Elzeany, B. E., & Wagieh, N. E. (2003). Stability indicating methods for the determination of aceclofenac. Farmaco, 58, 91-99.
8. Hauschke, D., Steinijans, V. W., & Diletti, E. (1990). A distribution free procedure for the statistical analysis of bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol., 28, 72-78.
9. Hinz, B., Auge, D., Rau, T., Rietbrock, S., Brune, K., & Werner, U. (2003). Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. Biomed. Chromatogr., 17, 268-275.
10. Lansdrop, D., Janssen, T. J., Guelen, P. J. M., & Vree, T. B. (1990). High performance liquid chromatographic method for the determination of diclofenac and its hydroxy metabolites in human plasma and urine. J. Chromatogr., 528, 487-494.
11. Lee, H. S., Jeong, C. K., Choi, S. J., Kim, S. B., Lee, M. H., Ko, G. I., & Sohn, D. H. (2000). Simultaneous determination of aceclofenac and diclofenac in human plasma by narrowbore HPLC using column-switching. J. Pharm. Biomed. Anal., 23, 775-781.
12. Legrand E. (2004). Aceclofenac in the management of inflammatory pain. Expert Opin. Pharmacother., 5, 1347-1357.
13. Najib, N., Idkaidek, N., Beshtawi, M., Bader, M., Admour, I., Alam, S., Zaman, Q., & Dham, R. (2004). Bioequivalence evaluation of two brands of aceclofenac 100 mg tablets (Aceclofar and Bristaflam) in healthy human volunteers. Biopharm. Drug. Dispos., 25, 103-108.
14. Nation, R. L., & Sansom, L. N. (1994). Bioequivalence requirements for generic products. Pharmacol. Ther., 62, 41-55.
15. Schulz, H. U., & Steinijans, V. W. (1992). Striving for standards in bioequivalence assessment: a review. Int. J. Clin. Pharmacol. Ther. Toxicol., 30, S1-S6.
16. Shah, V. P., Midha, K. K., & Sighe, S. (1992). Analytical method validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur. J. Drug Metab. Pharmacokin., 16, 249-255.
17. U.S. Food and Drug Administration. (2000). Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. Rockville, MD: Center for Drug Evaluation and Research.
18. Zawilla, N. H., Mohammad, M. A., El Kousy, N. M., & El-Moghazy Aly, S. M. (2002). Determination of aceclofenac in bulk and pharmaceutical formulations. J. Pharm. Biomed. Anal., 27, 243-251.